Up-regulation of asparagine synthetase expression is not linked to the clinical response to L-asparaginase in pediatric acute lymphoblastic leukemia

Blood

Volumn 107, Issue 11, 2006, Pages 4244-4249

  Appel, Inge M ^b   Den Boer, Monique L ^a   Meijerink, Jules P P ^b   Veerman, Anjo J P ^b   Reniers, Nathalie C M ^b   Pieters, Rob ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINE; ASPARTATE AMMONIA LIGASE; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; UPREGULATION;

EID: 33744497255     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2597     Document Type: Article

References (35)

1. Capizzi RL, Bertino JR, Skeel RT. L-asparaginase: clinical, biochemical, pharmacological and immunological status. Ann Int Medicine. 1971;74:893-901.
2. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei ED, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43:5601-5607.
3. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochemical Pharmacology. 1969;18:2578-2580.
4. Broome JD. L-asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treatment Reports. 1981;65:111-114.
5. Andrulis IL, Argonza R, Cairney AE. Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin. Somatic Cell Mol Genet. 1990;16:59-65.
6. Hutson RG, Kitoh T, Moraga Amador DA, Cosic S, Schuster SM, Kilberg MS. Amino acid control of asparagine synthetase: relation to resistance in human leukemia cells. Am J Physiol. 1997;272:1691-1699.
7. Aslanian AM, Kilberg MS. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 leukaemia cells. Biochem J. 2001;358:59-67.
8. Stams WAG, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1 negative, but not in TEL-AML1 positive pediatric acute lymphoblastic leukemia. Blood. 2005;105:4223-4225.
9. Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2003;101:2743-2747.
10. Veerman AJ, Hahlen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14:911-918.
11. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Ped Hematol/Oncol. 1999;2:6-12.
12. Boos J, Weber G, Ahlke E, Schulze-Westhof P, Nowak-Gottl U, Wurthwein G. Monitoring on asparaginase activity and asparaginase levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A:1544-1550.
13. Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Hematol. 2000;110:379-384.
14. Appel IM, Pinheiro JPV, Boer den ML, et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003;17:2254-2256.
15. Yoshimoto T, Nishimura H, Saito Y, et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res. 1986;77:1264-1270.
16. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205-2222.
17. Kaspers GJ, Veerman AJ, Pieters R, et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer. 1994;70:1047-1052.
18. Meijerink J, Mandigers C, Loch vd L, Tonissen E, Goodsaid F, Raemakers A. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn. 2001;3:55-61.
19. Horowitz B, Madras BK, Meister A, Old LJ, Boyse EA, Stockert E. Asparagine synthetase activity of mouse leukemias. Science. 1968;160:533-535.
20. Jousse C, Averous J, Bruhat A, Carraro V, Mordier S, Fafournoux P. Amino acids as regulators of gene expression: molecular mechanisms. Biochem Biophys Res Commun. 2004;313:447-452.
21. Chakrabarti R, Schuster SM. L-asparaginase: perspectives on the mechanisms of action and resistance. Int J Ped Hem/Oncol. 1997;4:597-611.
22. Irino T, Kitoh T, Koami K, et al. Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression. J Mol Diagn. 2004;6:217-224.
23. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J. 2001;357:321-328.
24. Wagner A, Boos J. Unphysiological effects contributing to asparaginase toxicity in vitro. Am J Physiol. 1998;274:C1185-1186.
25. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 childern with acute lymphoblastic leukemia: implications for treatment of infants. Leukemia. 1998;12:1344-1348.
26. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
27. Pieters R, den Boer ML. Molecular pharmacodynamics in childhood leukemia. Int J Hematol. 2003;78:402-413.
28. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990;76:2327-2336.
29. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88:4252-4258.
30. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL-AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094-1099.
31. Kaspers GJL, Veerman AJP, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhod acute lymphoblastic leukemia. Blood. 1997;90:2723-2729.
32. Barbosa-Tessmann IP, Chen C, Zhong C, et al. Activation of the human asparagine synthetase gene by the amino acid response and the endoplasmic reticulum stress response pathways occurs by common genomic elements. J Biol Chem. 2000;275:26976-26985.
33. Iiboshi Y, Papst PJ, Kawasome H, et al. Amino acid-dependent control of p70 s6k. J Biol Chem. 1999;274:1092-1099.
34. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
35. Fine BM, Kaspers GJL, Ho Minh, Loonen AH, Boxer LM. A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res. 2005;65:291-299.